Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

The interleukin‐6 pathway is up‐regulated in giant cell arteritis (GCA), Takayasu arteritis (TA), and polymyalgia rheumatica (PMR). We retrospectively assessed the outcomes of 10 patients with relapsing/refractory GCA, TA, or PMR treated with tocilizumab (TCZ).

[1]  D. Klatzmann,et al.  Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. , 2012, Arthritis and rheumatism.

[2]  D. Roccatello,et al.  Interleukin 6 Blockade as Steroid-sparing Treatment for 2 Patients with Giant Cell Arteritis , 2011, The Journal of Rheumatology.

[3]  K. Nishida,et al.  Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. , 2011, Investigative ophthalmology & visual science.

[4]  J. Zwerina,et al.  Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis , 2011, Annals of the rheumatic diseases.

[5]  S. Reichenbach,et al.  Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. , 2011, Swiss medical weekly.

[6]  C. Dejaco,et al.  Treatment of refractory adult-onset still’s disease with tocilizumab: report of two cases and review of the literature , 2011, Rheumatology International.

[7]  S. Beg,et al.  Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review , 2011, The Journal of Rheumatology.

[8]  G. Hunder,et al.  The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. , 2010, Arthritis and rheumatism.

[9]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[10]  M. Cid,et al.  Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis , 2010, Arthritis care & research.

[11]  K. Hagihara,et al.  Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica , 2010, The Journal of Rheumatology.

[12]  W. Paul,et al.  Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells , 2010, Science.

[13]  R. Olshen,et al.  Th17 and Th1 T-Cell Responses in Giant Cell Arteritis , 2010, Circulation.

[14]  R. Goel,et al.  Mycophenolate mofetil in Takayasu’s arteritis , 2010, Clinical Rheumatology.

[15]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[16]  T. Naka,et al.  Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. , 2008, Arthritis and rheumatism.

[17]  Amit Awasthi,et al.  IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells , 2008, Proceedings of the National Academy of Sciences.

[18]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[19]  M. López-Hoyos,et al.  Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. , 2008, Cytokine.

[20]  G. Hoffman,et al.  Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up , 2008, Annals of the rheumatic diseases.

[21]  H. Raspe,et al.  EULAR recommendations for the management of large vessel vasculitis , 2008, Annals of the rheumatic diseases.

[22]  N. Nishimoto,et al.  Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. , 2008, Arthritis and rheumatism.

[23]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[24]  P. Merkel,et al.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.

[25]  J. Nolla,et al.  Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. , 2007, Seminars in arthritis and rheumatism.

[26]  K. Maksimowicz-McKinnon,et al.  Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. , 2007, Arthritis and rheumatism.

[27]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[28]  S. K. Lee,et al.  Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. , 2006, Rheumatology.

[29]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[30]  T. Tedder,et al.  Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell Arteritis , 2004, The Journal of experimental medicine.

[31]  S. Gabriel,et al.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.

[32]  J. Jover,et al.  Disparate results in studies of methotrexate plus corticosteroids in the treatment of giant cell arteritis: comment on the article by Hoffman et al. , 2003, Arthritis and rheumatism.

[33]  T. Naka,et al.  The paradigm of IL-6: from basic science to medicine , 2002, Arthritis research.

[34]  K. Kalunian,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. , 2002, Arthritis and rheumatism.

[35]  M. Peterson,et al.  A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). , 2001, Clinical and experimental rheumatology.

[36]  J. Jover,et al.  Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.

[37]  J. Evans,et al.  Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. , 2000, Arthritis and rheumatism.

[38]  N. Ratliff,et al.  Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases. , 2000, Arthritis and rheumatism.

[39]  G. Remuzzi,et al.  Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? , 1999, Circulation.

[40]  E. Nordborg,et al.  No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. , 1998, British journal of rheumatology.

[41]  Y. Yazaki,et al.  Restricted Usage of T-Cell Receptor Vα-Vβ Genes in Infiltrating Cells in Aortic Tissue of Patients With Takayasu’s Arteritis , 1996 .

[42]  A. Fauci,et al.  Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. , 1994, Arthritis and rheumatism.

[43]  S. Bombardieri,et al.  Treatment of giant cell arteritis with cyclophosphamide pulses. , 1992, Journal of internal medicine.

[44]  K. Helmke,et al.  [Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy]. , 1992, Zeitschrift fur Rheumatologie.

[45]  B. Hazleman,et al.  Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. , 1986, Annals of the rheumatic diseases.

[46]  J. Shelhamer,et al.  Takayasu's arteritis and its therapy. , 1985, Annals of internal medicine.

[47]  R. W. Russell.  GIANT-CELL ARTERITIS , 1959 .

[48]  L. Magnani,et al.  Tocilizumab: a novel therapy for patients with large-vessel vasculitis. , 2012, Rheumatology.

[49]  Miho Suzuki,et al.  Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule , 2009, Rheumatology International.

[50]  内山 也寸志.  Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production , 2009 .

[51]  S. Hayat.  Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial , 2008 .

[52]  S. Hayat.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial , 2008 .

[53]  S. Ito,et al.  Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. , 2007, Internal medicine.

[54]  Sidor Misović,et al.  [Takayasu arteritis]. , 2005, Medicinski pregled.